These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 27079889)

  • 1. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abdominal submuscular implant of subcutaneous implantable cardioverter-defibrillator in a young child.
    Kwok SY; Yam N; Lun KS; Chen RH; Au TW; Yung TC
    Europace; 2018 Sep; 20(FI2):f248. PubMed ID: 29401320
    [No Abstract]   [Full Text] [Related]  

  • 3. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing.
    Payne JE; Badertscher P; Field ME; Sturdivant JL; Gold MR
    Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008631. PubMed ID: 32703008
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy.
    Hua W; Niu H; Fan X; Ding L; Xu YZ; Wang J; Chen K; Wang F; Zhang S;
    J Cardiovasc Electrophysiol; 2012 Nov; 23 Suppl 1():S5-9. PubMed ID: 23140347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C; Atienza F; Strasberg B; Arenal Á; Codner P; González-Torrecilla E; Datino T; Percal T; Almendral J; Ortiz M; Martins R; Martinez-Alzamora N; Fernandez Aviles F
    Cardiol J; 2015; 22(3):253-9. PubMed ID: 25179316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement.
    Mithani AA; Kath H; Hunter K; Andriulli J; Ortman M; Field J; Russo AM
    Europace; 2018 Feb; 20(2):308-314. PubMed ID: 28383717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iatrogenic Palpitations during Exercise in a Patient with a Dual Chamber Implantable Cardioverter-Defibrillator and Lead Dysfunction.
    Hasegawa K; Miyazaki S; Kaseno K; Tada H
    Int Heart J; 2019 Mar; 60(2):462-465. PubMed ID: 30626767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-shock oversensing by a subcutaneous defibrillator resulting in inappropriate withholding of post-shock bradycardia pacing.
    Maass AH; Van Gelder IC
    Europace; 2014 Jul; 16(7):1032. PubMed ID: 24792457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.